Top Gap Ups and Downs on Tuesday: TEM, MMM, DJT and More
GLP-1 Weight Loss Drugs Linked to a Wide Range of Health Benefits and Risks: Study
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
CFRA Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $90
Research: Weight loss drugs can also reduce the risk of Alzheimer's.
Recently, a large-scale study on popular weight loss drugs showed that patients using GLP-1 medications (such as Novo-Nordisk A/S's Ozempic and Wegovy, and Eli Lilly and Co's Mounjaro) had a 12% reduced risk of developing Alzheimer's disease, but there was an increase in the risk of arthritis, kidney, and pancreatic diseases.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}